Apellis Pharmaceuticals Inc
NASDAQ:APLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
US |
Relative Value
The Relative Value of one
APLS
stock under the Base Case scenario is
40.65
USD.
Compared to the current market price of 17.23 USD,
Apellis Pharmaceuticals Inc
is
Undervalued by 58%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
APLS Competitors Multiples
Apellis Pharmaceuticals Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
2.2B USD | 2.2 | 97.4 | 36.8 | 37.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.8B USD | 5.9 | 86.7 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.8B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.4B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD | 9.5 | 28.8 | 21.7 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.4B USD | 5.5 | 17.4 | 12.8 | 14.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR | 10.1 | 32.5 | 35 | 35.7 |